HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

prostaglandin endoperoxide receptor

Also Known As:
PG endoperoxide receptor; prostaglandin endoperoxide receptors; receptor, prostaglandin endoperoxide
Networked: 21 relevant articles (3 outcomes, 2 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1. Lerond, Laurence: 2 articles (03/2011 - 07/2010)
2. Castiglioni, Laura: 2 articles (03/2011 - 07/2010)
3. Blanc-Guillemaud, Vanessa: 2 articles (03/2011 - 07/2010)
4. Gelosa, Paolo: 2 articles (03/2011 - 07/2010)
5. Tremoli, Elena: 2 articles (03/2011 - 07/2010)
6. Sironi, Luigi: 2 articles (03/2011 - 07/2010)
7. Pignieri, Alice: 2 articles (03/2011 - 07/2010)
8. Thomas, Elizabeth A: 1 article (04/2012)
9. Tang, Bin: 1 article (04/2012)
10. Dean, Brian: 1 article (04/2012)

Related Diseases

1. Thrombosis (Thrombus)
11/01/1988 - "To address whether this modulates the response to TXA2 synthase inhibition in the setting of thrombosis in vivo, we examined the interaction of a TXA2 synthase inhibitor (U63,557a) and a TXA2/prostaglandin endoperoxide receptor antagonist (L636,499) in a canine model of coronary thrombosis after electrically induced endothelial injury. "
08/01/1991 - "Differential effects of thromboxane A2 synthase inhibition, singly or combined with thromboxane A2/prostaglandin endoperoxide receptor antagonism, on occlusive thrombosis elicited by endothelial cell injury or by deep vascular damage in canine coronary arteries."
04/25/1989 - "The beneficial effects of an antagonist of the thromboxane A2/prostaglandin endoperoxide receptor, 7-[2 alpha,4 alpha-(dimethylmethano)-6 beta-(2-cyclopentyl-2 beta- hydroxyacetamido)-1 alpha-cyclohexyl]-5(Z)-heptenoic acid (ONO-3708) on thrombosis were examined. "
02/01/1986 - "Therefore, reversal of coronary occlusion may reflect disaggregation of platelets and/or relaxation of vascular smooth muscle at the site of thrombus formation through specific antagonism of the thromboxane A2/prostaglandin endoperoxide receptor. "
08/01/1991 - "This study reveals 1) a differential efficacy of TXA2 synthase inhibition, singly or combined with TXA2/prostaglandin endoperoxide receptor antagonism, depending on the extent of the vessel wall lesion triggering thrombosis and the size of the thrombus required to obstruct the vascular lumen and 2) a significant synergism in preventing occlusive thrombosis of extensively damaged coronary arteries between strong TXA2 synthase inhibition and comparatively modest TXA2/prostaglandin endoperoxide receptor antagonism with ridogrel."
2. Stroke (Strokes)
3. Coronary Artery Disease (Coronary Atherosclerosis)
4. Myocardial Infarction
5. Coronary Occlusion

Related Drugs and Biologics

1. 3- ((6- amino- (4- chlorobenzenesulfonyl)- 2- methyl- 5,6,7,8- tetrahydronapht)- 1- yl)propionic acid
2. ridogrel
3. glucuronyl glucosamine glycan sulfate (Vessel)
4. Thromboxane A2 (A2, Thromboxane)
5. Prostaglandin-Endoperoxide Synthases (Cyclooxygenase)
6. Heparin (Liquaemin)
7. Aspirin (Acetylsalicylic Acid)
8. ONO 3708
9. sulotroban
10. Cyclooxygenase 2 (Cyclooxygenase-2)